Overview

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

Status:
Completed

Trial end date:
2015-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effect of canagliflozin (JNJ-28431754) on blood pressure reduction, compared to placebo, in patients with hypertension and type 2 diabetes mellitus and who are on stable doses of anti-hyperglycemic and anti-hypertensive agents. Overall safety and tolerability of canagliflozin will be assessed.

Phase:

Phase 4

Details

Lead Sponsor:

Janssen Scientific Affairs, LLC

Treatments:

Antihypertensive Agents
Canagliflozin
Hypoglycemic Agents